ILYANG PHARMACEUTICAL CO.,LTD Logo

ILYANG PHARMACEUTICAL CO.,LTD

Develops & manufactures drugs, vaccines & supplements for oncology & gastroenterology needs.

007570 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 하갈로 110, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1946, Ilyang Pharmaceutical is a research-driven company focused on the development and manufacturing of pharmaceutical products. The company's portfolio includes a wide range of prescription drugs, over-the-counter medications, vaccines, and health supplements. It has developed key products in therapeutic areas such as oncology, gastroenterology, and circulatory system disorders. Notable developments include Supect®, a new chemical entity for the treatment of leukemia, and Noltec®, an anti-ulcer agent. Ilyang emphasizes high-quality production through advanced manufacturing facilities and a commitment to innovation in addressing global health needs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ILYANG PHARMACEUTICAL CO.,LTD and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-11 00:00
Legal Proceedings Report
회계처리기준위반에따른검찰고발등조치
Korean 7.0 KB
2025-09-11 00:00
Legal Proceedings Report
기타시장안내 (상장적격성 실질심사 사유 발생)
Korean 4.9 KB
2025-09-11 00:00
Legal Proceedings Report
[기재정정]기타시장안내 (상장적격성 실질심사 사유 발생)
Korean 8.2 KB
2025-09-10 00:00
Regulatory News Service
매매거래정지및정지해제(풍문등조회공시)
Korean 5.1 KB
2025-09-10 00:00
Legal Proceedings Report
조회공시요구(풍문또는보도)
Korean 3.5 KB
2025-09-05 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 13.1 KB
2025-08-18 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 27.7 KB
2025-08-18 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 19.8 KB

Automate Your Workflow. Get a real-time feed of all ILYANG PHARMACEUTICAL CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ILYANG PHARMACEUTICAL CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea 140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea 432980
Mithra Pharmaceuticals S.A. Logo
Biotech firm developing pharma for women's health: contraception, fertility, and menopause.
Belgium MITRA
MIZUHO MEDY CO.,LTD. Logo
Develops rapid diagnostic tests & gene analyzers for clinical, research & agricultural markets.
Japan 4595
MOA Life Plus Co. Ltd. Logo
Develops immunotherapies & consumer solutions for immunity, skin rejuvenation, and pet care.
South Korea 142760
Moberg Pharma Logo
Develops & commercializes a leading topical treatment for nail fungus for European markets.
Sweden MOB
Mochida Pharmaceutical Co.,Ltd. Logo
An R&D-driven company making drugs, skincare, and medical equipment for specialized fields.
Japan 4534
Develops LNP drug delivery systems for severe diseases, offering R&D to GMP manufacturing support.
South Korea 322970
MORISHITA JINTAN CO.,LTD. Logo
Manufactures health products and provides OEM/ODM services using advanced encapsulation technology.
Japan 4524
MUROMACHI CHEMICALS INC. Logo
A diversified manufacturer of pharmaceuticals, chemical systems, health foods & functional materials.
Japan 4885

Talk to a Data Expert

Have a question? We'll get back to you promptly.